Application of Tucatinib and Trastuzumab: Dual Anti HER2 Therapy Against HER2 Positive Breast Cancer

Synergism in action of tucatinib and trastumab is reported in breast cancer management. However, its molecular basis is yet to be determined. In this context we attempted to provide an explanation at the molecular level by performing in silico experimentation and coupling its result with already available published observations. Our study will provide basis for planning further experimental study for unravelling the truth.

Automated summary

This study attempted to explain the synergistic action of tucatinib and trastumab in breast cancer treatment at the molecular level by performing in silico experimentation and combining the results with existing observations, providing a basis for further experimental studies.